PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -- Marketing Authorization Application (MAA) ...

If you're looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) ...

Our findings suggest that GLP-1 therapy holds real promise. While a randomized trial is still needed, the fact that many patients with IIH already qualify for GLP-1s due to diabetes or obesity means ...

GLP-1 medications can be effective for weight loss and diabetes management but require lifestyle changes and can have severe ...

Sarah Marriott, who lives with Type 1 diabetes, argues that research must ensure equal access to new technologies.

GLP-1s were first approved in 2005 for the treatment of Type 2 diabetes. Since then, more versions of the medication have hit the market, becoming more accessible to patients and used for a wider ...

Type 1 diabetes has shifted from a condition once associated with early mortality to a chronic disease owing to the development of intensive insulin therapy, continuous glucose monitoring, and hybrid ...

GLP-1 receptor agonists have largely contributed to revolutionising pharmacological therapy of type 2 diabetes. They are among the most potent glucose-lowering agents, while also eliciting bodyweight ...